DALLAS, April 22, 2026 - Scientific research teams from Mass General Brigham Heart and Vascular Institute in Boston, Cincinnati Children's Hospital Center and the University of Pittsburgh will lead a new $15 million initiative dedicated to better understanding how to diagnose and treat heart valve disease . The Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease is the latest research network funded by the American Heart Association, a global force changing the future of health for all.
According to the American Heart Association's 2026 Heart Disease and Stroke Statistics , more than 80 million people worldwide are living with some type of heart valve disease, and the numbers are climbing. In the U.S., the condition contributes to more than 57,000 deaths each year.
Heart valve disease is a common cardiovascular condition in which one or more of the heart's four valves are narrowed and restrict blood flow or do not close properly which causes blood to flow backward rather than into the heart chambers or large blood vessels.
The American Heart Association (AHA) has funded a new, four‑year, $15 million research initiative aimed at improving the early detection and slowing progression of valvular heart disease.
The program, termed the Strategically Focused Research Network on Earlier Detection and Delaying Progression of Valvular Heart Disease, began April 1, 2026, and will be led by investigator teams at three academic centers: Mass General Brigham Heart and Vascular Institute (Boston), Cincinnati Children’s Hospital Medical Center, and the University of Pittsburgh.
The awards will support collaborative projects across these centers.
The AHA frames this network as its latest targeted research network among a portfolio developed to tackle priority cardiovascular and cerebrovascular knowledge gaps.
The stated aim is to enhance understanding of how to detect valvular heart disease at earlier stages and to identify approaches that may delay disease progression.
The AHA cites rising global prevalence and substantial mortality burden as motivating factors: a recent AHA statistic report referenced in the source indicates over 80 million people worldwide are living with some form of valvular heart disease, and in the United States the condition is implicated in more than 57,000 deaths annually.
The AHA emphasizes the natural history of valvular disease—its increasing incidence with age, tendency to progress asymptomatically, and potential to lead to adverse clinical states if untreated—as the clinical gap the network seeks to address.
Hilaire, Ph.D., FAHA, director of the Center for Integrative Valve Science and associate professor of medicine.
The source lists these investigators by institutional affiliation and role; it notes that the three centers will undertake collaborative research projects under the awards.
Specific project titles, hypotheses, protocols, or individual aims were not detailed in the source.
The network is described as one of the AHA’s Strategically Focused Research Networks (SFRNs), a model previously used by the organization to concentrate resources on defined, high‑priority research themes.
Historically, SFRNs comprise three to six research centers and pair expertise across basic, clinical, and population/behavioral sciences to address prevention, diagnosis, and treatment of the targeted condition.
The announcement indicates this network will follow that collaborative, multidisciplinary approach; however, the source does not specify particular study designs, cohorts, sample sizes, experimental methods, or analytic plans to be employed by the funded teams.
The source summarizes clinical features of valvular heart disease as a group of conditions in which one or more cardiac valves become narrowed, restricting forward flow (stenosis), or fail to close properly, permitting blood to regurgitate.
It states that untreated valvular dysfunction can progress to heart failure, arrhythmia, repeated hospitalizations, diminished life quality, and premature death.
The AHA emphasizes that valvular disease prevalence rises with age and frequently remains asymptomatic until advanced stages, thus limiting therapeutic options once clinical symptoms manifest.
The network’s focus on earlier detection and slowing progression is presented as a strategy to expand opportunities for intervention and to avert downstream complications.
The AHA places this award within a broader history of programmatic research support.
The announcement notes that the Association has invested nearly $300 million to establish 19 Strategically Focused Research Networks to date, addressing topics such as prevention, hypertension, women’s heart health, heart failure, obesity, vascular disease, atrial arrhythmias, cardiometabolic health, health technology, cardio‑oncology, inflammatory mechanisms, and cardio‑renal‑metabolic interactions.
In addition, the AHA reports having funded more than $6.1 billion in cardiovascular, cerebrovascular, and brain‑health research since 1949, positioning itself as a major non‑governmental funder in the United States.
The source asserts that the Association’s prior funding has generated knowledge that has had practical impact on public health, though no specific studies or findings are detailed in this announcement.
Stacey E.
Rosen, M.D., FAHA, identified as the AHA volunteer president and executive director of the Katz Institute for Women’s Health, is quoted as highlighting the urgency of earlier detection because valvular disease often lacks overt early warnings and can be advanced by the time symptoms appear.
She characterizes the new network as a vehicle to extend the AHA’s prior quality improvement and clinical programs—such as the Heart Valve Initiative and Target: Aortic Stenosis—by supporting scientific exploration oriented to earlier disease stages.
The announcement expresses anticipation that the collaborative centers will generate new knowledge, but it does not forecast specific outcomes.
The AHA frames the network’s potential value in terms of earlier recognition of valvular disease and interventions to delay progression, with the broader goal of improving patient care and preventing complications.
The source links this funding to prior AHA efforts in quality improvement and education relating to valvular disease, indicating institutional intent to translate new scientific findings into clinical and systems‑level programs.
Specific pathways for translation from the planned research to practice, however, are not detailed in the source.